Polen Capital Management LLC lowered its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 12.2% during the fourth quarter, Holdings Channel reports. The fund owned 59,861 shares of the company’s stock after selling 8,308 shares during the period. Polen Capital Management LLC’s holdings in GeneDx were worth $7,786,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in WGS. Jones Financial Companies Lllp lifted its position in shares of GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares in the last quarter. Ramirez Asset Management Inc. acquired a new stake in shares of GeneDx in the fourth quarter valued at approximately $33,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of GeneDx in the fourth quarter valued at approximately $35,000. Quarry LP raised its position in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after purchasing an additional 209 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in GeneDx during the 4th quarter worth $73,000. Institutional investors and hedge funds own 61.72% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on WGS. Craig Hallum restated a “buy” rating and set a $85.00 target price on shares of GeneDx in a research report on Tuesday, May 5th. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. BTIG Research cut their target price on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Weiss Ratings lowered shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Finally, Guggenheim dropped their price target on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and an average target price of $96.43.
GeneDx Price Performance
GeneDx stock opened at $60.99 on Friday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $1.81 billion, a P/E ratio of -22.76 and a beta of 1.96. The business has a 50-day moving average of $55.07 and a 200-day moving average of $90.41. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87.
GeneDx (NASDAQ:WGS – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The firm had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. During the same period in the previous year, the company posted ($0.23) EPS. On average, equities analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current year.
Insider Transactions at GeneDx
In other GeneDx news, Director Casdin Capital, Llc acquired 185,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the transaction, the director owned 3,367,164 shares of the company’s stock, valued at $143,441,186.40. This trade represents a 5.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Keith A. Meister bought 533,758 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were bought at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the acquisition, the director directly owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 77,287 shares valued at $5,153,215. 29.60% of the stock is currently owned by insiders.
GeneDx News Summary
Here are the key news stories impacting GeneDx this week:
- Positive Sentiment: Hedge fund interest may be supportive for sentiment, as reports say Eli Casdin is loading up on GeneDx shares. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
- Neutral Sentiment: Several law firms reiterated that a class action has been filed against GeneDx and that investors have until August 3, 2026 to seek lead-plaintiff status. Investor Alert: Pomerantz Law Firm Reminds Investors…
- Neutral Sentiment: Additional notices from Rosen, Faruqi & Faruqi, Schall, Robbins LLP, and others kept the securities-fraud case in the spotlight, reinforcing legal overhang rather than adding new operational news. ROSEN, TOP RANKED INVESTOR COUNSEL…
- Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares on June 9, though the company said the sales were to cover tax withholding tied to equity vesting. CEO Form 4 Filing
GeneDx Company Profile
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Read More
- Five stocks we like better than GeneDx
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS – Free Report).
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
